Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus (Q34856870)

4 August 2017

1 reference

title

Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus (English)

1 reference

4 August 2017

0 references

0 references

1 reference

1 reference

2

Gerald I Shulman

1 reference

4 August 2017

1

Kitt F Petersen

1 reference

PubMed ID

12231074

4 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

American Journal of Cardiology

4 August 2017

1 reference

4 August 2017

90

1 reference

4 August 2017

11G-18G

1 reference

4 August 2017

5A

1 reference

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Pathogenesis of NIDDM. A balanced overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Mechanism of free fatty acid-induced insulin resistance in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Cellular mechanisms of insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Life without white fat: a transgenic mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Mechanism of insulin resistance in A-ZIP/F-1 fatless mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

The role of TNFalpha and TNF receptors in obesity and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Adipose tissue as an endocrine and paracrine organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

The hormone resistin links obesity to diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Mechanism of troglitazone action in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Mechanism by which metformin reduces glucose production in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902554-7

10.1016/S0002-9149(02)02554-7

7 January 2021

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12231074